beta-lactams has been researched along with meropenem in 184 studies
| Studies (beta-lactams) | Trials (beta-lactams) | Recent Studies (post-2010) (beta-lactams) | Studies (meropenem) | Trials (meropenem) | Recent Studies (post-2010) (meropenem) |
|---|---|---|---|---|---|
| 7,579 | 179 | 3,395 | 3,803 | 284 | 2,253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.09) | 18.2507 |
| 2000's | 39 (21.20) | 29.6817 |
| 2010's | 111 (60.33) | 24.3611 |
| 2020's | 32 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Gutmann, L; Kitzis, MD; Zhou, XY | 1 |
| Schumacher, UK; Single, B | 1 |
| Collatz, E; Delettré, J; Frénois, F; Jarlier, V; L'Hermite, G; Pernot, L; Petrella, S; Rybkine, T; Sougakoff, W | 1 |
| Banzai, M; Chimura, T; Sato, S; Satou, S; Yamakawa, M | 1 |
| Gunderson, B; Hermsen, ED; Hovde, LB; Ibrahim, KH; Rotschafer, JC; Rotschafer, SE | 1 |
| Agnifili, A; Amicosante, G; Franceschini, N; Franchino, L; Perilli, M; Rossolini, GM; Segatore, B; Setacci, D | 1 |
| Burgess, DS; Hall, RG | 1 |
| Calvo, F; Canduela, MJ; Gallego, L; Martín, G; Pujana, I; Sevillano, E; Umaran, A | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Daikos, GL; Giakkoupi, P; Legakis, NJ; Miriagou, V; Petrikkos, G; Tzouvelekis, LS; Vatopoulos, AC | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Lemaire, S; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP | 1 |
| Falagas, ME; Galanakis, E; Kateifidis, A; Leventakos, K; Mantadakis, E; Maraki, S; Samonis, G; Spanaki, AM; Tselentis, Y | 1 |
| Albertí, S; Alonso, D; Borrell, N; Doménech-Sánchez, A; Gomez, C; Padilla, E; Pérez, JL | 1 |
| Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP | 1 |
| Satti, F; Shames, R; Smith, MA; Vellozzi, EM | 1 |
| Hernández, JR; Martínez-Martínez, L; Pascual, A; Romero, L; Velasco, C | 1 |
| Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
| Banevicius, MA; DeRyke, CA; Fan, HW; Nicolau, DP | 1 |
| Falagas, ME; Manta, KG; Siempos, II; Vardakas, KZ | 1 |
| Broide, E; Raveh, D; Rudensky, B; Yinnon, AM | 1 |
| Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
| Chen, YS; Chiu, CJ; Chu, C; Lee, CH; Liu, JW; Su, LH | 1 |
| Billal, DS; Hotomi, M; Yamanaka, N | 1 |
| Lister, PD | 1 |
| Cielecka-Piontek, J; Jelińska, A; Zajac, M | 1 |
| Beloborodov, VB; Eliseeva, EV; Grigor'ev, KB; Iakovlev, SV; Iakovlev, VP; Kon, EM; Kostina, GV; Kuprenkov, AV; Levit, AL; Mukhacheva, SIu; Saturnov, AV; Sergeev, IN; Sidorenko, SV; Spasov, GP; Stakanov, AV; Ushakova, MA | 1 |
| Nicolau, DP | 1 |
| Shah, PM | 1 |
| Giamarellou, H | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Sciandra, M; Siccardi, M | 1 |
| Charlier, C; Denooz, R | 1 |
| Joseph, J; Rodvold, KA | 1 |
| Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
| Blanchet, B; Chhun, S; Jullien, V; Lanternier, F; Legrand, T; Pons, G; Rey, E; Zahar, JR | 1 |
| Carey, PR; Kalp, M | 1 |
| Ahsman, MJ; Mathot, RA; Tibboel, D; Wildschut, ED | 1 |
| Ansaloni, L; Catena, F; Gazzotti, F; Nanetti, A; Nardo, B; Pezzilli, R; Pinna, AD; Santini, D | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
| Amyes, SG; Evans, BA; Hamouda, A; Towner, KJ | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Giske, CG; Haldorsen, B; Samuelsen, Ø; Sundsfjord, AS; Vading, M | 1 |
| Carattoli, A; García-Fernández, A; Giordano, A; Mancini, C; Miriagou, V; Papagiannitsis, CC; Venditti, M | 1 |
| Buyle, F; Claus, B; Robays, H; Vogelaers, D | 1 |
| Borgianni, L; Docquier, JD; Hanson, ND; Prandi, S; Rossolini, GM; Salden, L; Santella, G | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Chumjan, W; Hajjar, E; Mahendran, KR; Schulte, A; Suginta, W; Weingart, H; Winterhalter, M | 1 |
| Crandon, JL; Nicolau, DP | 1 |
| Cai, J; Liu, J; Wu, D | 1 |
| Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
| Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Hsueh, PR; Huang, WH; Ko, WC; Lee, NY; Tsui, KC | 1 |
| Dihmess, A; Evans, A; Fiorenza, M; Graffunder, E; Harrington, S; Lodise, TP; Martis, P; Masoud, R; McNutt, LA; Patel, N; Woo, B | 1 |
| Agodi, A; Koumaki, V; Poulou, A; Pournaras, S; Sofianou, D; Themeli-Digalaki, K; Tsakris, A; Voulgari, E; Vrioni, G | 1 |
| Cotton, F; De Backer, D; Jacobs, F; Macours, P; Seyler, L; Taccone, FS; Vincent, JL | 1 |
| Amyes, SG; Dancer, SJ; Findlay, J; Hamouda, A | 1 |
| Gonçalves-Pereira, J; Póvoa, P | 1 |
| Chang, SC; Chen, WC; Chen, YC; Hu, FC; Wang, JL; Wu, UI; Yang, CS | 1 |
| Hsueh, PR; Huang, WH; Ko, WC; Lee, CC; Lee, NY; Tsui, KC | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
| Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
| Boyle, F; Boyle, L; Brisse, S; Burns, K; Condon, I; Cormican, M; Delannoy-Vieillard, AS; Finnegan, C; Humphreys, H; Khan, A; Monahan, R; Morris, C; Morris, D; Morris-Downes, M; O'Connell, N; O'Gorman, A; Powell, J; Power, L; Turton, J; Woodford, N | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Ho, MW; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Tang, HJ; Toh, HS; Wang, JH; Yu, KW | 1 |
| Liu, EM; Oelschlaeger, P; Pegg, KM | 1 |
| Drobniewski, F; Gonzalo, X | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
| Koh, TH; Krishnan, PU; Lim, TP; Lye, D; Marimuthu, K; Ng, TM; Tan, TY; Teng, C | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Chen, Y; Du, X; Fu, Y; Ji, J; Wang, H; Yu, Y | 1 |
| Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
| Kim, DH; Yoon, H | 1 |
| Ahuja, V; Balasubramanian, V; Balganesh, M; Bhattacharjee, D; Dinesh, N; Ganguly, S; Kumar, N; Panduga, V; Parab, M; Ramachandran, V; Reddy, J; Shandil, R; Sharma, S; Solapure, S; Vishwas, KG | 1 |
| El-Ghaiesh, S; Farrell, J; Hamlett, J; Jenkins, RE; Meng, X; Monshi, MM; Naisbitt, DJ; Park, BK; Peckham, D; Pirmohamed, M; Sanderson, JP; Whitaker, P; Yaseen, FS | 1 |
| Cao, X; Chen, H; Chen, J; Fang, Y; Lao, X; Shen, B; Shi, Y; Yu, Y; Zheng, H | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
| Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
| Hidalgo, G; Hidalgo, M; Jugo, MB; Maccallini, GC; Villar, HE; Visser, M | 1 |
| Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
| Barth, AL; da Silva, RC; Dalarosa, MG; Falci, DR; Luz, DI; Magagnin, CM; Ribeiro, VB; Rozales, FP; Sampaio, JM; Vieira, FJ; Zavascki, AP | 1 |
| Calvo, G; Llauradó-Serra, M; Martín-Loeches, I; Pontes, C; Soy, D; Ulldemolins, M; Vaquer, S | 1 |
| Danishuddin, M; Faheem, M; Khan, A; Khan, AU | 1 |
| Bowler, IC; Buchanan, R; Crook, D; Stoesser, N | 1 |
| Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
| Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL | 1 |
| Bai, KJ; Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
| Abbey, A; Farrar, H; Nair, R; Patel, V | 1 |
| Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
| Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
| Graves, B; Hajkowicz, K; Paterson, DL; Stewart, A; Ta, K | 1 |
| Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
| Cipolla, A; D'Abramo, A; D'Agostino, C; Gizzi, F; Iannetta, M; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Tierno, F; Trinchieri, V; Vullo, V | 1 |
| Chongtrakool, P; Diraphat, P; Malathum, K; Pornsinchai, P; Siripanichgon, K | 1 |
| Arora, R; Chakotiya, AS; Chawla, R; Goel, R; Narula, A; Sharma, RK; Tanwar, A; Thakur, P | 1 |
| Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
| Fattouh, R; McGeer, A; Melano, RG; Patel, SN; Poutanen, SM; Tijet, N | 1 |
| Albornoz, E; Bahr, G; Corso, A; Gonzalez, LJ; Pasteran, F; Vila, AJ | 1 |
| Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
| Jeon, YL; Kang, SY; Kim, MH; Lee, MY; Lee, WI | 1 |
| Cipolla, A; D'Abramo, A; De Angelis, M; Favaro, M; Ferretti, G; Gizzi, F; Iannetta, M; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Vullo, V | 1 |
| Alegria, L; Andresen, M; Andresen-Vasquez, M; Chan, PH; Downey, P; Leung, YC; Silva, C; Soto, D; Tapia, P; Wong, KY; Wong, WT | 1 |
| Caio, C; Gona, F; Mezzatesta, ML; Salerno, I; Stefani, S; Zingali, T | 1 |
| Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
| Boelens, J; Catteeuw, J; Claeys, G; De Bus, L; De Waele, JJ; Decruyenaere, J; Denys, W; Depuydt, PO; Gadeyne, B; Vermeulen, K | 1 |
| Bridge, L; Brown-Elliott, BA; Killingley, J; Vasireddy, S; Wallace, RJ | 1 |
| Aktaş, Z; Akyön, Y; Aşçı Toraman, Z; Ay, S; Ayaş, R; Aydemir, Ş; Aydın, F; Bakıcı, Z; Bayramoğlu, G; Baysallar, M; Büyüktaş, A; Çağatay, M; Çakar, A; Çelik, C; Çöplü, N; Dündar, D; Erçal, BD; Güdücüoğlu, H; Gülay, Z; Günaydın, M; Gür, D; Hasdemir, U; Karatuna, O; Kayacan, Ç; Kılıç, A; Kılıç, H; Öğünç, D; Özhak Baysan, B; Parlak, M; Tünger, A; Yanık, K; Zer, Y | 1 |
| Brul, S; Feng, Y; Jonker, MJ; Moustakas, I; Ter Kuile, BH | 1 |
| Hu, Q; Hu, Y; Lin, X; Lv, H; Xu, X; Zhang, R | 1 |
| Aruanno, A; Buonomo, A; Centrone, M; Di Rienzo, A; Mezzacappa, S; Nucera, E; Pascolini, L; Pecora, V; Ricci, AG; Rizzi, A; Schiavino, D | 1 |
| de Jonge, BL; Karlowsky, JA; Kazmierczak, KM; Nichols, WW; Sahm, DF | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Hsiao, FY; Pai, TY; Shen, LJ; Wu, CC; Wu, FL | 1 |
| Arai, K; Kashiwa, M; Nagano, N; Saito, R; Yamada, K | 1 |
| Furuyama, T; Hanson, ND; Ishii, Y; Nonomura, H; Shimizu-Ibuka, A | 1 |
| Fridlund, J; Schön, T; Woksepp, H | 1 |
| Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
| Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL | 1 |
| Di Maggio, T; Docquier, JD; Landini, G; Pallecchi, L; Rossolini, GM; Sergio, F | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Cantón, R; Chang, KT; Gao, S; Ledesma, KR; Oliver, A; Phe, K; Sánchez-Díaz, AM; Tam, VH; Van Bambeke, F; Zamorano, L; Zhou, J | 1 |
| Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
| D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
| Raghunand, TR; Viswanathan, G; Yadav, S | 1 |
| Fakhar, Z; Govender, T; Honarparvar, B; Kruger, HG; Lamichhane, G; Maguire, GEM; Walker, RC | 1 |
| Baroncelli, S; Bartoloni, A; Farese, A; Luise, F; Mancini, A; Nozzoli, C; Pieralli, F; Rossolini, GM; Sammicheli, L | 1 |
| Fredborg, M; Sondergaard, TE; Wang, M | 1 |
| Elzanfaly, ES; Fayed, AS; Hendawy, HAM; Salama, NN; Salem, MY; Youssif, RM | 1 |
| Almirante, B; Campany, D; Fàbrega, A; Fox, ML; González-López, JJ; Larrosa, N; Miguel, L; Mir, A; Piedra-Carrasco, N; Ruiz-Camps, I; Viñado, B | 1 |
| Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND | 1 |
| Martin, NI; Tehrani, KHME | 1 |
| Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL | 1 |
| Keller, PM; Müller, DM; Rominski, A; Sander, P; Schulthess, B | 1 |
| Buscher, H; Gentili, S; Imani, S; Marriott, D; Sandaradura, I | 1 |
| Achard, MES; Anderson, GJ; Djoko, KY; Hancock, SJ; Harris, PN; Lo, AW; McEwan, AG; Miraula, M; Mitić, N; Paterson, DL; Peters, KM; Phan, MD; Prombhul, S; Schembri, MA; Schenk, G; Shafer, WM; Sidjabat, HE; Walsh, TR | 1 |
| Abboud, MI; Brem, J; Claridge, TDW; Dmitrienko, GI; Hinchliffe, P; Johnson, JW; Kosmopoulou, M; Krismanich, AP; Schofield, CJ; Spencer, J | 1 |
| Hatti, M; Odenholt, I; Resman, F; Solomonidi, N; Tham, J | 1 |
| Gasper, J; Held, K; Manoil, C; Morgan, S; Siehnel, R; Singh, P | 1 |
| An, G; Bach, T; D'Cunha, R; Li, P; Nalbant, D; Winokur, P; Young, BA; Zhang, J | 1 |
| Caetano, T; Covas, C; Mendo, S; Santos, T; Viana, AT | 1 |
| Ally, M; Briscoe, S; Lipman, J; McWhinney, B; Roberts, JA; Ungerer, J; Wong, G | 1 |
| Billot, L; Brett, SJ; Cotta, MO; Davis, JS; De Waele, JJ; Dulhunty, JM; Finfer, S; Glass, P; Knowles, S; Lipman, J; McGuinness, S; Myburgh, J; Paterson, DL; Peake, S; Rajbhandari, D; Rhodes, A; Roberts, JA; Shirwadkar, C; Starr, T; Taylor, C | 1 |
| Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
| Adang, EMM; Bruggemann, R; Dan Do, TN; Kolwijck, E; Nguyen, CP; Ten Oever, J; Wertheim, HFL | 1 |
| Bhandari, P; Nwaiser, C; Sameed, M; Schmalzle, SA | 1 |
| Cheng, MP; Lawandi, A; Lee, TC; Lefebvre, B; Leite, G; Longtin, J | 1 |
| Cobian, J; Hall, B; Miller, J; Wilson, K | 1 |
| Caroline, C; Chien-Boon Lye, D; Choon-Kiat Tan, N; Ding, YY; Hsien-Xiong Lee, R; Lim, JP; Neo, HY; Pei-Ying Ho, E; Tan, KT; Wei-Han Ng, D | 1 |
| Bogiel, T; Gospodarek-Komkowska, E; Sêkowska, A; Woźniak, M | 1 |
| Bar-David, E; Ben-Shmuel, A; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Guddat, L; Liu, X; Lu, Z; Rao, Z; Schofield, CJ; Wang, H; Yang, C; Yang, H; Zhang, A; Zhou, W | 1 |
| Chatzopoulou, F; Malousi, A; Meletis, G; Metallidis, S; Politi, L; Poulou, A; Protonotariou, E; Skoura, L; Tsakris, A | 1 |
| Delattre, IK; Dugernier, T; Hites, M; Jacobs, F; Laterre, PF; Spapen, H; Taccone, FS; Wallemacq, PE | 1 |
| Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
| Benken, LA; Chamberlain, AR; Jones, RL; Kaplan, JM; Murphy, ME; Stoneman, EM; Tang Girdwood, SC; Tang, PH; Vinks, AA | 1 |
| Beatty, KE; Levine, SR | 1 |
| Alharbi, M; Alharbi, O; Biboy, J; Derrick, JP; Gallagher, LA; Grunert, T; Ingmer, H; Liu, H; Mayer, K; McBain, AJ; Mikkelsen, K; Nøhr-Meldgaard, K; O'Gara, JP; Sirisarn, W; Vestergaard, M; Vollmer, W; Xia, G | 1 |
| Booncharoen, S; Chaiyapoke, C; Chanawong, A; Lulitanond, A; Srisrattakarn, A; Tavichakorntrakool, R; Tippayawat, P; Wongthong, S | 1 |
| Anderson, WE; Hammer, J; Heffner, AC; Jaffa, RK; Medaris, LA; Pillinger, KE | 1 |
| Blumenthal, KG; Fu, X; Mancini, CM; Naureckas Li, C; Zhang, Y | 1 |
| Burgess, DS; Clark, JA; Landmesser, KB | 1 |
| Besch, G; Capellier, G; Chaignat, C; Clairet, AL; Despres, C; Floury, SP; Labro, G; Lagoutte-Renosi, J; Montange, D; Piton, G; Puyraveau, M; Vettoretti, L; Vivet, B; Winiszewski, H | 1 |
| Armstrong, T; Fenn, SJ; Hardie, KR | 1 |
| Chen, X; Guo, S; Li, Y; Liang, X; Su, H; Tan, X; Xi, J | 1 |
| Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| De Cock, PAJG; De Paepe, P; Delanghe, JR; Dhont, E; Herck, I; Stove, V; Van Der Heggen, T; Vanhaesebrouck, S; Verstraete, AG; Willems, J | 1 |
| Batchelder, HR; Lamichhane, G; Nuermberger, EL; Panthi, CM; Rimal, B; Story-Roller, E; Tabor, C; Townsend, CA | 1 |
| Abruzzi, J; Kopczynski, A; Montes, THM; Nedel, WL; Portela, LV; Rodolphi, MS; Strogulski, NR | 1 |
| DeZotell, L; Elledge, S; Guy, J; Holmes, AK; Klindworth, K | 1 |
| Chen, W; Li, GB; Li, R; Mou, L; Qian, S; Su, H; Wang, Z; Yan, YH; Yang, H; Yang, L; Zhou, C | 1 |
| Errington, J; Flores-Rodriguez, N; Iredell, J; Martinez-Martin, D; Mickiewicz, K; Petrovic Fabijan, A; Venturini, C | 1 |
| Azanza Perea, JR; Sádaba Díaz de Rada, B | 1 |
| Béranger, A; Bille, E; Callot, D; Chouchana, L; Debray, A; Hirt, D; Oualha, M; Renolleau, S; Tréluyer, JM | 1 |
| Alexander, KM; Alshaer, MH; Felton, TW; Manigaba, K; Maranchick, N; Mathew, SK; Peloquin, CA; Shoulders, BR | 1 |
| Barranco, R; Cabanillas, B; Fernández-Crespo, J; García-Moguel, I; Marín, L; Mielgo, R; Moya, B; Peñalver, MJ | 1 |
| Freret, C; Le Terrier, C; Nordmann, P; Poirel, L; Seigneur, M | 1 |
| Fraikin, N; Rousseau, CJ; Van Melderen, L; Zedek, S | 1 |
17 review(s) available for beta-lactams and meropenem
| Article | Year |
|---|---|
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aminoglycosides; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Humans; Immunocompetence; Intensive Care Units; Meropenem; Pneumonia, Bacterial; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiration, Artificial; Survival Rate; Thienamycins; Treatment Outcome | 2007 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
beta-Lactams without a suicide inhibitor.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillins; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Cefpirome; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Infections; Meropenem; Piperacillin; Thienamycins | 2011 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Humans; Meropenem; Piperacillin; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2014 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Cost-Benefit Analysis; Gram-Negative Bacterial Infections; Humans; Meropenem | 2019 |
JMM Profile: Carbapenems: a broad-spectrum antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Meropenem | 2021 |
Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Child; Drug Therapy, Combination; Febrile Neutropenia; Female; Humans; Imipenem; Male; Meropenem; Network Meta-Analysis; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.
Topics: Adult; Albumins; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood Proteins; Catechols; Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Humans; Iron; Meropenem | 2022 |
6 trial(s) available for beta-lactams and meropenem
| Article | Year |
|---|---|
[Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Costs and Cost Analysis; Cross Infection; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Meropenem; Metronidazole; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Russia; Thienamycins; Treatment Outcome | 2006 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-Mediated Hypersensitivity to β-Lactams.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Cross Reactions; Drug Hypersensitivity; Ertapenem; Female; Humans; Imipenem; Immunoglobulin E; Male; Meropenem; Middle Aged; Skin Tests; Thienamycins | 2016 |
A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
Topics: Anti-Bacterial Agents; Australia; beta-Lactams; Critical Illness; Drug Administration Schedule; Humans; Infusions, Intravenous; Meropenem; New Zealand; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis; Treatment Outcome; United Kingdom | 2019 |
Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactams; Child; Critical Illness; Humans; Infant; Meropenem; Piperacillin, Tazobactam Drug Combination; Risk Factors | 2022 |
161 other study(ies) available for beta-lactams and meropenem
| Article | Year |
|---|---|
Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Microbial; Humans; Hydrolysis; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1993 |
Susceptibility of the anaerobic gram-negative non-sporulating rod, Bilophila wadsworthia to beta-lactams, beta-lactamase inhibitors, meropenem, metronidazole, clindamycin and quinolones.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Clindamycin; Gram-Negative Anaerobic Straight, Curved, and Helical Rods; Meropenem; Metronidazole; Microbial Sensitivity Tests; Quinolones; Thienamycins | 1998 |
Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem.
Topics: Amino Acid Sequence; Apoenzymes; beta-Lactamases; beta-Lactams; Binding Sites; Crystallization; Crystallography, X-Ray; Dimerization; Hydrogen Bonding; Kinetics; Meropenem; Models, Molecular; Molecular Sequence Data; Pliability; Protein Conformation; Pseudomonas aeruginosa; Sequence Alignment; Thienamycins; Water | 2001 |
[Pyogenic sacroiliitis in pregnancy].
Topics: Adult; Anti-Bacterial Agents; Arthritis, Infectious; beta-Lactams; Female; Humans; Lactams; Meropenem; Pregnancy; Pregnancy Complications, Infectious; Sacroiliac Joint; Suppuration; Thienamycins | 2001 |
Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Drug Resistance, Microbial; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Mutation; Pharmacogenetics; Probability; Sensitivity and Specificity; Streptococcus pneumoniae; Thienamycins | 2003 |
Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Colony Count, Microbial; Cross Infection; DNA, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genes, Bacterial; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Sequence Analysis, DNA; Thienamycins | 2004 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
[Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Spain; Thienamycins | 2004 |
Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Drug Resistance, Bacterial; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Quality Control; Reproducibility of Results; Thienamycins | 2005 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Blood Bactericidal Activity; Dose-Response Relationship, Drug; Ertapenem; Lactams; Listeria monocytogenes; Meropenem; Microbial Sensitivity Tests; Staphylococcus aureus; Thienamycins | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Topics: Anti-Bacterial Agents; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2005 |
Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Candida albicans; Ertapenem; Gastrointestinal Tract; Imipenem; Male; Meropenem; Mice; Mice, Inbred ICR; Thienamycins | 2006 |
Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Colony Count, Microbial; Imipenem; In Vitro Techniques; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Plasmids; Pneumonia, Bacterial; Porins; Rats; Rats, Wistar; Thienamycins; Treatment Outcome | 2006 |
Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Topics: beta-Lactamases; beta-Lactams; Brazil; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Thienamycins | 2006 |
Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Ertapenem; Eye; Meropenem; Microbial Sensitivity Tests; Propionibacterium acnes; Rabbits; Thienamycins | 2006 |
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spain; Thienamycins | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
Topics: Animals; beta-Lactamases; beta-Lactams; Disease Models, Animal; Ertapenem; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Mice; Microbial Sensitivity Tests; Thienamycins | 2007 |
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Interactions; Ertapenem; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2007 |
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cephalosporins; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Electroporation; Ertapenem; Female; Genotype; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cephalosporins; Haemophilus influenzae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2007 |
A comparison of the stability of ertapenem and meropenem in pharmaceutical preparations in solid state.
Topics: Algorithms; beta-Lactams; Chromatography, High Pressure Liquid; Drug Packaging; Drug Stability; Drug Storage; Dyphylline; Entropy; Ertapenem; Humidity; Meropenem; Molecular Structure; Pharmaceutical Preparations; Reference Standards; Tandem Mass Spectrometry; Temperature; Thienamycins; Time Factors; Validation Studies as Topic | 2008 |
A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting.
Topics: Anti-Bacterial Agents; beta-Lactams; Chromatography, High Pressure Liquid; Ertapenem; Humans; Meropenem; Reproducibility of Results; Sensitivity and Specificity; Thienamycins; Ultraviolet Rays | 2008 |
Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cefuroxime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftazidime; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Imipenem; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Crystallography, X-Ray; Ertapenem; Imipenem; Meropenem; Molecular Structure; Solutions; Spectrum Analysis, Raman; Thienamycins | 2008 |
Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Cefazolin; Cefotaxime; Ceftriaxone; Chromatography, High Pressure Liquid; Humans; Infant, Newborn; Meropenem; Tandem Mass Spectrometry; Thienamycins; Vancomycin | 2009 |
Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats.
Topics: Animals; Antibiotic Prophylaxis; Bacterial Infections; beta-Lactams; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ertapenem; Male; Meropenem; Pancreatitis, Acute Necrotizing; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Thienamycins | 2009 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Novel genetic context of multiple bla OXA-58 genes in Acinetobacter genospecies 3.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blotting, Southern; DNA Transposable Elements; DNA, Bacterial; DNA, Ribosomal Spacer; Ertapenem; Gene Duplication; Gene Order; Genes, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Restriction Mapping; Sequence Analysis, DNA; Thienamycins | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Disk Diffusion Antimicrobial Tests; Ertapenem; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Microbiological Techniques; Thienamycins | 2011 |
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Electrophoresis, Polyacrylamide Gel; Ertapenem; Imipenem; Klebsiella pneumoniae; Meropenem; Molecular Sequence Data; Porins; Thienamycins | 2010 |
Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Administration Routes; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2010 |
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
Topics: Amino Acid Sequence; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ertapenem; Meropenem; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Pseudomonas aeruginosa; Sequence Homology, Amino Acid; Thienamycins; United States | 2011 |
Molecular analysis of antimicrobial agent translocation through the membrane porin BpsOmp38 from an ultraresistant Burkholderia pseudomallei strain.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Outer Membrane Proteins; beta-Lactams; Biological Transport; Burkholderia pseudomallei; Cefepime; Ceftazidime; Cephalosporins; Ertapenem; Humans; Imipenem; Kinetics; Lipid Bilayers; Melioidosis; Meropenem; Models, Molecular; Molecular Sequence Data; Norfloxacin; Penicillin G; Phospholipids; Porins; Protein Conformation; Sequence Homology, Amino Acid; Thienamycins | 2011 |
Pharmacodynamic approaches to optimizing beta-lactam therapy.
Topics: Adult; Animals; Anti-Bacterial Agents; beta-Lactams; Child; Computer Simulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Kidney; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins; Time Factors | 2011 |
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Chi-Square Distribution; Confidence Intervals; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Thienamycins | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 2011 |
Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Case-Control Studies; Drug Utilization; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Meropenem; Middle Aged; Risk Factors; Thienamycins | 2011 |
Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of klebsiella pneumoniae carbapenemase-producing enterobacteriaceae clinical isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Boronic Acids; Enterobacteriaceae; Enterobacteriaceae Infections; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Phenotype; Sensitivity and Specificity; Thienamycins | 2011 |
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Female; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2011 |
Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactams; Catheter-Related Infections; Conjugation, Genetic; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Gene Expression Profiling; Gene Transfer, Horizontal; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Molecular Weight; Mutation; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic; Thienamycins; Urinary Tract Infections; Urine | 2012 |
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Propensity Score; Thienamycins | 2012 |
Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Topics: Adult; Bacteremia; beta-Lactams; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Retrospective Studies; Thienamycins; Young Adult | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
Inter-hospital outbreak of Klebsiella pneumoniae producing KPC-2 carbapenemase in Ireland.
Topics: beta-Lactamases; beta-Lactams; Disease Outbreaks; Ertapenem; Genes, Bacterial; Hospitals; Humans; Imipenem; Ireland; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Polymerase Chain Reaction; Thienamycins | 2012 |
Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Linear Models; Meropenem; Microbial Sensitivity Tests; Prevalence; Prospective Studies; Taiwan; Thienamycins | 2012 |
The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure.
Topics: Adaptation, Biological; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Biological Evolution; Drug Resistance, Bacterial; Kinetics; Meropenem; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutation; Thienamycins | 2012 |
Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Clavulanic Acid; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Thienamycins; Tuberculosis, Multidrug-Resistant | 2013 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Case-Control Studies; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Risk Factors; Thienamycins; Treatment Outcome | 2013 |
In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactams; Cefoperazone; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Unusual drug reaction between valproate sodium and meropenem.
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Bacterial Infections; beta-Lactams; Drug Interactions; Drug Monitoring; Epilepsy; Ertapenem; Humans; Male; Meropenem; Thienamycins; Valproic Acid | 2013 |
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; beta-Lactams; Clavulanic Acid; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Streptomycin; Thienamycins; Treatment Outcome; Tuberculosis, Pulmonary | 2013 |
β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis.
Topics: Aztreonam; beta-Lactamase Inhibitors; beta-Lactams; Cystic Fibrosis; Drug Hypersensitivity; Haptens; Humans; Hypersensitivity; Meropenem; Molecular Structure; Piperacillin; Serum Albumin; T-Lymphocytes; Thienamycins | 2013 |
Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Hydrolysis; Kinetics; Meropenem; Molecular Docking Simulation; Recombinant Fusion Proteins; Thienamycins | 2013 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
[In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Thienamycins | 2014 |
Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Disease Susceptibility; Drug Resistance, Multiple; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Providencia; Thienamycins | 2014 |
Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2).
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Line; Ertapenem; HeLa Cells; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Binding; Thienamycins | 2014 |
Multidrug-resistant Escherichia coli soft tissue infection investigated with bacterial whole genome sequencing.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Diagnosis, Differential; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Floxacillin; Follow-Up Studies; Genome, Bacterial; Gentamicins; Humans; Liver Diseases; Male; Meropenem; Middle Aged; Sequence Analysis, DNA; Soft Tissue Infections; Thienamycins; Treatment Outcome; Vancomycin | 2014 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sepsis; Serum; Thienamycins; Treatment Outcome | 2015 |
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Taiwan; Thienamycins | 2015 |
Osteomyelitis, discitis, epidural and psoas abscess secondary to Salmonella enterica in a man with diabetes mellitus and newly diagnosed α-thalassaemia trait.
Topics: Aged; alpha-Thalassemia; Anti-Bacterial Agents; beta-Lactams; Diabetes Mellitus, Type 2; Discitis; Ertapenem; Humans; Laminectomy; Male; Meropenem; Osteomyelitis; Psoas Abscess; Salmonella enterica; Thienamycins; Treatment Outcome | 2015 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
The Use of Therapeutic Drug Monitoring to Optimize Treatment of Carbapenem-Resistant Enterobacter Osteomyelitis.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; C-Reactive Protein; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Ertapenem; Female; Fosfomycin; Humans; Meropenem; Middle Aged; Osteomyelitis; Staphylococcal Infections; Staphylococcus epidermidis; Thienamycins | 2015 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sepsis; Thienamycins | 2016 |
EMERGENCY ROOM: AN UNRECOGNIZED SOURCE OF EXTENDED-SPECTRUM β-LACTAMASE PRODUCING ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Plasmids; Thailand; Thienamycins; Young Adult | 2015 |
Camellia sinensis Ameliorates the Efficacy of Last Line Antibiotics Against Carbapenem Resistant Escherichia coli.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactams; Camellia sinensis; Carbapenems; Colistin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Flavonoids; Free Radical Scavengers; Meropenem; Microbial Sensitivity Tests; Minocycline; Phytochemicals; Plant Extracts; Plant Leaves; Thienamycins; Tigecycline | 2016 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Enterobacter; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Klebsiella; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Thienamycins | 2015 |
Triton Hodge Test: Improved Protocol for Modified Hodge Test for Enhanced Detection of NDM and Other Carbapenemase Producers.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Detergents; Ertapenem; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Octoxynol; Sensitivity and Specificity; Thienamycins | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
A Case of Sepsis in a 92-Year-Old Korean Woman Caused by Aerococcus urinae and Identified by Sequencing the 16S Ribosomal RNA Gene.
Topics: Aerococcus; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Meropenem; Remission Induction; RNA, Ribosomal, 16S; Sepsis; Sequence Analysis, RNA; Thienamycins; Urinary Tract Infections | 2016 |
Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Kidney Transplantation; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Surgical Wound Infection; Thienamycins | 2016 |
Method Based on the β-Lactamase PenPC Fluorescent Labeled for β-Lactam Antibiotic Quantification in Human Plasma.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Biosensing Techniques; Drug Monitoring; Fluorescence; Healthy Volunteers; Humans; Meropenem; Sus scrofa; Thienamycins | 2016 |
Colistin Increases the Cidal Activity of Antibiotic Combinations Against Multidrug-Resistant Klebsiella pneumoniae: An In Vitro Model Comparing Multiple Combination Bactericidal Testing at One Peak Serum Concentration and Time-Kill Method.
Topics: Anti-Bacterial Agents; beta-Lactams; Colistin; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Predictive Value of Tests; Rifampin; Thienamycins; Tigecycline | 2016 |
Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Drug Resistance, Microbial; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2016 |
In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Nocardia; Nontuberculous Mycobacteria; Thienamycins | 2016 |
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Phenotype; Thienamycins; Turkey | 2016 |
Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftazidime; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Meropenem; Microbial Sensitivity Tests; Mutation; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2016 |
Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing β-lactamase KPC-2 from China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; China; DNA, Bacterial; Ertapenem; Female; Genotype; Hospitals; Humans; Hydrolysis; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2016 |
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
Topics: Africa; Amikacin; Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactams; Ceftazidime; Colistin; Drug Combinations; Humans; Latin America; Meropenem; Microbial Sensitivity Tests; Middle East; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
Topics: Anti-Bacterial Agents; Anticonvulsants; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Interactions; Ertapenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Valproic Acid | 2016 |
Comparison of the Modified-Hodge test, Carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity; Thienamycins | 2016 |
Structural and Mutagenic Analysis of Metallo-β-Lactamase IMP-18.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Kinetics; Meropenem; Mutagens; Pseudomonas aeruginosa; Thienamycins | 2016 |
A microbiological method for determining serum levels of broad spectrum β-lactam antibiotics in critically ill patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacteriological Techniques; beta-Lactams; Chromatography, Liquid; Critical Illness; Humans; Mass Spectrometry; Meropenem; Microbial Sensitivity Tests; Sweden; Thienamycins | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Hospitals; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Thienamycins | 2016 |
Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory Pathogens.
Topics: Acetylcysteine; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Drug Combinations; Drug Interactions; Enterobacter cloacae; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Thienamycins | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Humans; Kinetics; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tandem Mass Spectrometry; Thienamycins | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Clavulanic Acid; Dibenzothiepins; Drug Resistance, Microbial; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Thienamycins; Tuberculosis | 2017 |
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.
Topics: beta-Lactams; Carbapenems; Ertapenem; Imipenem; Meropenem; Molecular Dynamics Simulation; Mycobacterium tuberculosis; Principal Component Analysis; Thienamycins | 2017 |
Every cloud has a silver lining.
Topics: Anti-Bacterial Agents; beta-Lactams; Diagnosis, Differential; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multiple Organ Failure; Thienamycins | 2017 |
Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Drug Synergism; Ertapenem; Humans; Meropenem; Polymyxins; Rifampin; Thienamycins | 2017 |
Zero and second-derivative synchronous fluorescence spectroscopy for the quantification of two non-classical β-lactams in pharmaceutical vials: Application to stability studies.
Topics: beta-Lactams; Chelating Agents; Ertapenem; Meropenem; Molecular Structure; Spectrometry, Fluorescence; Terbium; Thermodynamics; Thienamycins; Zirconium | 2017 |
Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; beta-Lactams; Drug Combinations; Ertapenem; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Sarcoma, Myeloid; Sepsis; Thienamycins; Transplantation, Homologous; Treatment Outcome | 2018 |
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2017 |
Thiol-Containing Metallo-β-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefoperazone; Drug Resistance, Bacterial; Gram-Negative Bacteria; Meropenem; Molecular Structure; Sulfhydryl Compounds; Thienamycins | 2017 |
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Ertapenem; Gentamicins; Humans; Imipenem; Italy; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Thienamycins; Tigecycline | 2017 |
Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; Cephalosporins; Drug Stability; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Thienamycins | 2017 |
Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clostridium Infections; Cohort Studies; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Floxacillin; Humans; Incidence; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurotoxicity Syndromes; Piperacillin; Retrospective Studies; Thienamycins | 2017 |
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants.
Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Coordination Complexes; Copper; Ertapenem; Escherichia coli; Humans; Ions; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2018 |
Cyclobutanone Mimics of Intermediates in Metallo-β-Lactamase Catalysis.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Catalysis; Cyclobutanes; Meropenem; Molecular Mimicry; Nuclear Magnetic Resonance, Biomolecular; Thienamycins | 2018 |
Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bacterial Infections; beta-Lactams; Cefotaxime; Drug Monitoring; Female; Humans; Length of Stay; Male; Meropenem; Patient Readmission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis; Sweden; Thienamycins | 2018 |
Determinants of Extreme β-Lactam Tolerance in the Burkholderia pseudomallei Complex.
Topics: beta-Lactams; Burkholderia pseudomallei; Meropenem; Peptidoglycan | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam | 2018 |
Environmental superbugs: The case study of Pedobacter spp.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Drug Resistance, Microbial; Ertapenem; Escherichia coli; Humans; Meropenem; Microbial Sensitivity Tests; Pedobacter; Thienamycins | 2018 |
Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Drug Monitoring; Female; Humans; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Prospective Studies; Treatment Outcome | 2018 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Meropenem; Penicillins; Stevens-Johnson Syndrome; Treatment Outcome | 2019 |
In vitro synergy of β-lactam combinations against KPC-producing Klebsiella pneumoniae strains.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Drug Synergism; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2019 |
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Centers for Medicare and Medicaid Services, U.S.; Early Diagnosis; Early Medical Intervention; Emergency Service, Hospital; Female; Guideline Adherence; Hospital Mortality; Hospitalization; Humans; Male; Medical Overuse; Meropenem; Middle Aged; Patient Care Bundles; Piperacillin, Tazobactam Drug Combination; Reimbursement Mechanisms; Retrospective Studies; Sepsis; Shock, Septic; Soft Tissue Infections; Time-to-Treatment; United States; Urinary Tract Infections; Vancomycin | 2020 |
Higher rates of carbapenem-related seizures in older hospitalised adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Logistic Models; Male; Meropenem; Seizures; Singapore | 2020 |
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests | 2020 |
Using old antibiotics to treat ancient bacterium-β-lactams for Bacillus anthracis meningitis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bacteria; beta-Lactamase Inhibitors; beta-Lactams; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Rabbits; Sulbactam | 2020 |
Structures of
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Crystallography, X-Ray; Drug Design; Meropenem; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium tuberculosis; Penicillin-Binding Proteins; Protein Binding; Protein Domains; Recombinant Proteins; Tuberculosis | 2020 |
Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Genotyping Techniques; Greece; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Proteus Infections; Proteus mirabilis; Tertiary Care Centers; Whole Genome Sequencing; Young Adult | 2020 |
What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Computer Simulation; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Shock, Septic | 2020 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Cefepime; Child; Child, Preschool; Comorbidity; Critical Illness; Feasibility Studies; Female; Humans; Intensive Care Units, Pediatric; Male; Meropenem; Piperacillin; Prospective Studies | 2021 |
Investigating β-Lactam Drug Targets in
Topics: beta-Lactams; Humans; Meropenem; Mycobacterium tuberculosis; Penicillin-Binding Proteins; Pharmaceutical Preparations | 2021 |
The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Cefoxitin; Cell Wall; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Larva; Lipopolysaccharides; Membrane Proteins; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Animal; Moths; Mutation; Octoxynol; Oxacillin; Penicillin-Binding Proteins; Peptidoglycan; Phenotype; Staphylococcal Infections; Teichoic Acids; Virulence | 2021 |
Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin
Topics: Anti-Bacterial Agents; beta-Lactams; Cefotaxime; Drug Synergism; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2021 |
Empiric aztreonam is associated with increased mortality compared to beta-lactams in septic shock.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; APACHE; Aztreonam; beta-Lactams; Cefepime; Cohort Studies; Drug Hypersensitivity; Female; Fluoroquinolones; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Shock, Septic | 2021 |
Association of beta-lactam allergy documentation and antibiotic use in patients with febrile neutropenia.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Cross-Sectional Studies; Drug Hypersensitivity; Febrile Neutropenia; Humans; Meropenem; Penicillins | 2021 |
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
β-lactam dosing at the early phase of sepsis: Performance of a pragmatic protocol for target concentration achievement in a prospective cohort study.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Meropenem; Piperacillin; Prospective Studies; Sepsis | 2022 |
Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Singapore | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
T405, a New Penem, Exhibits
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous | 2022 |
Antibiotic therapy does not alter mitochondrial bioenergetics in lymphocytes of patients with septic shock - A prospective cohort study.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clavulanic Acid; Energy Metabolism; Humans; Lymphocytes; Meropenem; Mitochondria; Piperacillin, Tazobactam Drug Combination; Polymyxins; Prospective Studies; Shock, Septic; Vancomycin | 2022 |
Evaluating the Effects of Ertapenem and Meropenem on Tacrolimus.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Meropenem; Retrospective Studies; Tacrolimus | 2023 |
Design, Synthesis, and Biological Evaluation of New 1H-Imidazole-2-Carboxylic Acid Derivatives as Metallo-β-Lactamase Inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carboxylic Acids; Imidazoles; Meropenem; Monobactams; Thiazoles | 2022 |
L-Form Switching in Escherichia coli as a Common β-Lactam Resistance Mechanism.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Escherichia coli; Escherichia coli Proteins; Meropenem; Muramidase; Penicillin-Binding Proteins | 2022 |
Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Topics: Anti-Bacterial Agents; Bayes Theorem; beta-Lactams; Cefotaxime; Child; Critical Illness; Humans; Infusions, Intravenous; Meropenem; Piperacillin; Prospective Studies | 2023 |
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Sepsis | 2023 |
Meropenem allergy testing performed at the bedside of hospitalized patients labelled with a penicillin allergy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Drug Hypersensitivity; Female; Humans; Hypersensitivity; Male; Meropenem; Middle Aged; Penicillins; Retrospective Studies; Skin Tests | 2023 |
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Escherichia coli; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Are envelope stress responses essential for persistence to β-lactams in
Topics: Anti-Bacterial Agents; beta-Lactams; Escherichia coli; Escherichia coli Proteins; Meropenem | 2023 |